B. Braun Announces Approval and Commercialization of First Generic Sugammadex Injection in the U.S. Market
BETHLEHEM, Pa., July 14, 2026 /PRNewswire/ -- B. Braun Medical Inc. (B. Braun), a recognized leader in smart infusion therapy and pharmaceutical manufacturing, announced the U.S. Food and Drug Administration (FDA) approval of Sugammadex Injection, 200 mg/2 mL (100 mg/mL), AP-rated generic...
BETHLEHEM, Pa., July 14, 2026 /PRNewswire/ -- B. Braun Medical Inc. (B. Braun), a recognized leader in smart infusion therapy and pharmaceutical manufacturing, announced the U.S. Food and Drug Administration (FDA) approval of Sugammadex Injection, 200 mg/2 mL (100 mg/mL), AP-rated generic...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.